IgG Antibodies to GlcNAc β and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment.

MLA

Smorodin, Eugeniy, et al. “IgG Antibodies to GlcNAc β and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment.” Disease Markers, vol. 2018, Dec. 2018, p. 4639805. EBSCOhost, https://doi.org/10.1155/2018/4639805.

APA

Smorodin, E., Sergeyev, B., Kurtenkov, O., Kuznetsova, T., & Geller, J. (2018). IgG Antibodies to GlcNAc β and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment. Disease Markers, 2018, 4639805. https://doi.org/10.1155/2018/4639805

Chicago

Smorodin, Eugeniy, Boris Sergeyev, Oleg Kurtenkov, Tatiana Kuznetsova, and Julia Geller. 2018. “IgG Antibodies to GlcNAc β and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment.” Disease Markers 2018 (December): 4639805. doi:10.1155/2018/4639805.